Standard
Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention : an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk". / Ridker, P.M.; MacFadyen, J.G.; Nordestgaard, Børge G; Koenig, W.; Kastelein, J.J.P.; Genest, J.; Glynn, R.J.; Ridker, Paul M; Macfadyen, Jean G; Koenig, Wolfgang; Kastelein, John J P; Genest, Jacques; Glynn, Robert J.
I:
Circulation. Cardiovascular Quality and Outcomes, Bind 3, Nr. 5, 09.2010, s. 447-52.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
Ridker, PM, MacFadyen, JG
, Nordestgaard, BG, Koenig, W, Kastelein, JJP, Genest, J, Glynn, RJ, Ridker, PM, Macfadyen, JG, Koenig, W, Kastelein, JJP, Genest, J & Glynn, RJ 2010, '
Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk"',
Circulation. Cardiovascular Quality and Outcomes, bind 3, nr. 5, s. 447-52.
https://doi.org/10.1161/CIRCOUTCOMES.110.938118APA
Ridker, P. M., MacFadyen, J. G.
, Nordestgaard, B. G., Koenig, W., Kastelein, J. J. P., Genest, J., Glynn, R. J., Ridker, P. M., Macfadyen, J. G., Koenig, W., Kastelein, J. J. P., Genest, J., & Glynn, R. J. (2010).
Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk".
Circulation. Cardiovascular Quality and Outcomes,
3(5), 447-52.
https://doi.org/10.1161/CIRCOUTCOMES.110.938118Vancouver
Ridker PM, MacFadyen JG
, Nordestgaard BG, Koenig W, Kastelein JJP, Genest J o.a.
Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk".
Circulation. Cardiovascular Quality and Outcomes. 2010 sep.;3(5):447-52.
https://doi.org/10.1161/CIRCOUTCOMES.110.938118Author
Ridker, P.M. ; MacFadyen, J.G. ; Nordestgaard, Børge G ; Koenig, W. ; Kastelein, J.J.P. ; Genest, J. ; Glynn, R.J. ; Ridker, Paul M ; Macfadyen, Jean G ; Koenig, Wolfgang ; Kastelein, John J P ; Genest, Jacques ; Glynn, Robert J. / Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention : an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk". I: Circulation. Cardiovascular Quality and Outcomes. 2010 ; Bind 3, Nr. 5. s. 447-52.
Bibtex
@article{3b21b58a400b497e9834fb2112536a3e,
title = "Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for {"}intermediate risk{"}",
abstract = "Recent primary prevention guidelines issued in Canada endorse the use of statin therapy among individuals at {"}intermediate risk{"} who have elevated levels of high-sensitivity C-reactive protein (hsCRP). However, trial data directly addressing whether this recommendation defines a patient population in which statin therapy is effective have not previously been published.",
author = "P.M. Ridker and J.G. MacFadyen and Nordestgaard, {B{\o}rge G} and W. Koenig and J.J.P. Kastelein and J. Genest and R.J. Glynn and Ridker, {Paul M} and Macfadyen, {Jean G} and Wolfgang Koenig and Kastelein, {John J P} and Jacques Genest and Glynn, {Robert J}",
year = "2010",
month = sep,
doi = "http://dx.doi.org/10.1161/CIRCOUTCOMES.110.938118",
language = "English",
volume = "3",
pages = "447--52",
journal = "Circulation: Cardiovascular Quality and Outcomes",
issn = "1941-7713",
publisher = "Lippincott Williams & Wilkins",
number = "5",
}
RIS
TY - JOUR
T1 - Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention
T2 - an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk"
AU - Ridker, P.M.
AU - MacFadyen, J.G.
AU - Nordestgaard, Børge G
AU - Koenig, W.
AU - Kastelein, J.J.P.
AU - Genest, J.
AU - Glynn, R.J.
AU - Ridker, Paul M
AU - Macfadyen, Jean G
AU - Koenig, Wolfgang
AU - Kastelein, John J P
AU - Genest, Jacques
AU - Glynn, Robert J
PY - 2010/9
Y1 - 2010/9
N2 - Recent primary prevention guidelines issued in Canada endorse the use of statin therapy among individuals at "intermediate risk" who have elevated levels of high-sensitivity C-reactive protein (hsCRP). However, trial data directly addressing whether this recommendation defines a patient population in which statin therapy is effective have not previously been published.
AB - Recent primary prevention guidelines issued in Canada endorse the use of statin therapy among individuals at "intermediate risk" who have elevated levels of high-sensitivity C-reactive protein (hsCRP). However, trial data directly addressing whether this recommendation defines a patient population in which statin therapy is effective have not previously been published.
U2 - http://dx.doi.org/10.1161/CIRCOUTCOMES.110.938118
DO - http://dx.doi.org/10.1161/CIRCOUTCOMES.110.938118
M3 - Journal article
VL - 3
SP - 447
EP - 452
JO - Circulation: Cardiovascular Quality and Outcomes
JF - Circulation: Cardiovascular Quality and Outcomes
SN - 1941-7713
IS - 5
ER -
